In Q3 2025, Redmile Group held 34 positions worth $853.5M. They exited 53. Their largest holding was KRYS ($116.8M). Portfolio value grew +9.1% versus the prior quarter.
Frequently asked questions
What stocks did Redmile Group own in Q3 2025?
Redmile Group held 34 biotech stocks in their 13F portfolio in Q3 2025. Their top positions include KRYS, STOK, ZYME, ADCT, IMNM. The full holdings table is available on BiotechEdge with position sizes, quarter-over-quarter changes, and AI analysis.
How much was Redmile Group's portfolio worth in Q3 2025?
Redmile Group's tracked biotech portfolio was worth $853.5M across 34 positions, with total assets under management of approximately $6B. Portfolio values are based on 13F filings with the SEC.
What did Redmile Group buy in Q3 2025?
Redmile Group did not initiate any new positions in Q3 2025, but increased 4 existing holdings.
What did Redmile Group sell in Q3 2025?
Redmile Group fully exited 53 positions in Q3 2025, including ILMN, SRPT, ALGN, APLS, DCPH and 48 more. They also trimmed 17 existing positions.
Is Redmile Group a biotech fund?
Healthcare crossover fund investing from late-stage private rounds through public equity. Redmile manages a diversified book across biotech, medtech, and healthcare services, with a reputation for backing management teams through multiple rounds of financing.
Want AI analysis, insider signals, and catalyst overlays for Redmile Group?
View latest Redmile Groupportfolio →